Cell Response and Regulation Program (Project-002)

细胞反应和调节 摘要 细胞反应和调节（CRR）计划是一个以实验室为基础的基础科学计划，重点是 破译癌症的细胞机制CRR的实验方法包括生物化学， to work with patient病人tissues组织. CRR发现科学支持亨斯迈癌症研究所对遗传学的关注 和个性化肿瘤学，提供对癌症途径的见解，作为新的基础， 解决关键的临床问题。CRR成员的基本发现与癌症领域高度相关 预防、靶点鉴定、生物标记物开发、免疫学、诊断和治疗。 CRR研究的重点是1）细胞更新的调节; 2）异常信号传导的重要机制 在癌症和耐药性中;和3）细胞粘附、细胞迁移和转移。的主要资产 该计划是开发强大的癌症临床前模型，包括神经嵴的斑马鱼模型， 衍生的肿瘤和乳腺癌、肺癌、胰腺癌、脑癌和皮肤癌的小鼠模型，其中肿瘤是 在生理学背景下重新诱导。CRR成员还与临床同事合作， 异种移植模型，忠实地再现了患者来源的癌症的组织学和生物学行为。 本供资期内的主要成就包括： 执行细胞分裂，阐明参与上皮稳态和迁移的信号传导途径， 乳腺癌新生物标志物的鉴定，骨髓瘤耐药性的关键介质， 导致脑瘤和黑色素瘤转移的因素。CRR的基本发现正在导致早期阶段 乳腺癌和黑色素瘤的临床试验，并影响了结肠癌的化学预防试验。 CRR由道格拉斯格罗斯曼博士和凯瑟琳厄尔曼博士共同领导，共有26名成员， 12个犹他州部门在三个学院的大学，包括五个新成员谁是战略上 招募的值得注意的是，27%的CRR成员是MD/PhD或MD，带来了额外的临床视角。在 2013年，CRR成员每年为癌症研究项目提供980万美元的资金，其中34%来自NCI （从2008年的11%增加了两倍）。自2009年7月以来，获得了16项新的合作赠款， 在212篇出版物中报告了这一情况（18%为方案内合作，37%为方案间合作）。所有正式成员 (100%）获得了同行评审的资金，许多人获得了杰出的奖项。 癌症中心通过提供最先进的设施来增强该计划的目标， 资源、方案资金和征聘支助。在未来五年内，CRR计划将 通过促进科学家之间富有成效的互动，继续促进以癌症为重点的协同研究 和临床医生，并培养具有临床应用潜力的基于CRR的研究发现。

CELL RESPONSE AND REGULATION PROGRAM ABSTRACT The Cell Response and Regulation (CRR) Program is a laboratory-based basic science program focused on deciphering cellular mechanisms involved in cancer. CRR's experimental approaches range from biochemistry to work with patient tissues. CRR discovery science supports Huntsman Cancer Institute's focus on genetics and individualized oncology by providing insights into cancer pathways that serve as new foundations to address critical clinical issues. CRR members' basic discoveries are highly relevant to the areas of cancer prevention, target identification, biomarker development, prognostics, diagnostics, and therapy. CRR Research focuses on mechanisms important in 1) regulation of cell turnover; 2) aberrant signaling in cancer and drug resistance; and 3) cell adhesion, cell migration, and metastasis. A major asset of the Program is the development of robust preclinical models of cancer, including zebrafish models of neural crest- derived tumors and mouse models of breast, lung, pancreatic, brain, and skin cancers, in which tumors are induced de novo in a physiologic context. CRR members also collaborate with clinical colleagues to develop xenograft models that faithfully recapitulate the histology and biologic behavior of patient-derived cancers. Major achievements in this funding period include improved understanding of the machinery that executes cell division, elucidation of signaling pathways involved in epithelial homeostasis and migration, and identification of a new biomarker for breast cancer, a critical mediator of drug resistance in myeloma, and factors that drive brain tumor and melanoma metastasis. Basic CRR discoveries are leading to early phase clinical trials in breast cancer and melanoma and have impacted a chemoprevention trial in colon cancer. Co-Led by Douglas Grossman, MD, PhD, and Katharine Ullman, PhD, CRR has 26 members from 12 University of Utah departments in three colleges, including five new members who were strategically recruited. Notably, 27% of CRR members are either MD/PhDs or MDs, bringing added clinical perspective. In 2013, CRR members had $9.8M in annual total funding for cancer research projects, including 34% from NCI (tripled from 11% in 2008). Since July 2009, 16 new collaborative grants were obtained, and CRR research was reported in 212 publications (18% intra- and 37% inter-programmatic collaborations). All full members (100%) have peer-reviewed funding, and many have received distinguished awards. The Cancer Center enhances the Program's goals by providing state-of-the-art facilities, Shared Resources, programmatic funds, and support for recruitments. Over the next five years, the CRR Program will continue to foster synergistic cancer-focused research by facilitating productive interactions between scientists and clinicians, and to cultivate CRR-based research discoveries with potential for clinical application.